市場調查報告書
商品編碼
1422062
細胞治療市場機會與預測(2017-2031):依治療類型、細胞類型、產品類型、應用、最終使用者和地區Cell Therapy Market Assessment, By Therapy Type, By Cell Type, By Product, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F |
全球細胞治療市場規模預計將從 2023 年的 46.7 億美元增至 2031 年的 129.3 億美元,預測期內複合年增長率為 13.56%。
關鍵驅動因素包括慢性病盛行率上升、研發投資增加、細胞治療技術持續進步、支持性監管環境、合作關係和擴大應用。 需求增加背後的原因是世界各地慢性病的增加。 隨著這些疾病的增加,對創新和有效治療的需求不斷增長,而細胞療法被定位為一種有前途的解決方案。
慢性病盛行率的上升是全球細胞治療市場的關鍵驅動力。 50歲及以上患有至少一種慢性病的人數正在顯著增加,預計到2050年將從2020年的7152.2萬人增加99.5%,達到1.4266億。 這種人口結構的變化意味著迫切需要先進且有效的治療幹預措施,而細胞療法已成為一種有前景的解決方案。 此外,預計患有多種疾病的患者人數將從2020年的783.04萬人增加到2050年的1496.8萬人,增長91.16%,加劇了老齡化社會面臨的健康挑戰的複雜性。 為了解決日益增長的健康負擔,對創新細胞療法的需求不斷增加,市場定位於應對不斷變化的醫療保健格局,並為慢性病管理提供有針對性的解決方案。
各大公司正在建立最先進的生產設施,並對細胞療法進行重大投資。 這項措施反映了人們對細胞治療潛力的信心,是全球細胞治療市場的關鍵驅動力。 對最先進的製造設施的大量投資將提高生產能力和可擴展性,從而更有效和更廣泛地提供基於細胞的療法。 該行業巨頭積極主動地推動創新,促進全球細胞治療市場的整體成長和成熟,並鞏固其作為醫療保健領域變革力量的地位。
世界各國政府正與領先公司合作,促進全球細胞治療市場的成長。 這些合作夥伴關係旨在利用政府的支持和專業知識來推進細胞療法的研究、開發和可及性。 透過促進此類合作,政策制定者正在為創新創造有利的環境,加速監管審批,並確保這些先進的醫療幹預措施得到廣泛採用。 政府和主要行業參與者之間的協同反映了共同承諾,即充分發揮細胞療法的潛力,徹底改變醫療保健並應對全球範圍內的挑戰。
本報告調查了全球細胞治療市場,提供市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析、案例研究、競爭格局、主要公司的簡介等等。
Global cell therapy market size was valued at USD 4.67 billion in 2023, expected to reach USD 12.93 billion in 2031, with a CAGR of 13.56% for the forecast period between 2024 and 2031. Several factors propel the global cell therapy market, creating an exciting and high-potential environment. Key drivers include the rising prevalence of chronic diseases, increasing investments in research and development, continuous advancements in cell therapy technologies, a supportive regulatory environment, collaborative partnerships, and growing applications. A prominent force behind the growing demand is the increasing prevalence of chronic diseases worldwide. As these conditions become more prevalent, there is an increasing demand for innovative and effective treatments, positioning cell therapy as a promising solution.
Pharmaceutical companies and research institutions are investing significant amounts in exploring the vast potential of cell therapies. This financial commitment fosters groundbreaking discoveries and accelerates the development of novel treatments. Advancements in cell therapy technologies are further contributing to this dynamic landscape. Breakthrough technologies such as CRISPR gene editing are enhancing the precision and efficacy of cell therapies, opening new possibilities for therapeutic interventions across various medical domains in global cell therapy market. A supportive regulatory environment acts as a catalyst, streamlining approval processes and encouraging companies to invest in the development of cell-based treatments, boosting the growth of the global cell therapy market. Collaborative partnerships between pharmaceutical/biotech firms, and academic institutions leverage collective strengths, fostering innovation and expediting the commercialization of promising therapies. As cell therapy applications continue to broaden from oncology to neurodegenerative diseases, the global awareness and acceptance of these innovative treatments are on the rise.
The increasing prevalence of chronic diseases is a significant catalyst for the global cell therapy market. As the population aged 50 and above faces a staggering increase in the incidence of at least one chronic disease, the numbers are projected to surge by 99.5%, reaching 142.66 million by 2050 from 71.522 million in 2020. The demographic shift signifies an urgent need for advanced and effective therapeutic interventions, with cell therapy emerging as a promising solution. Moreover, the projection of a 91.16% increase in individuals with multimorbidity-from 7.8304 million in 2020 to 14.968 million in 2050, highlights the complexity of health challenges an aging population faces. In response to the growing health burden, the demand for innovative cell therapies is rising, positioning the market to address the evolving healthcare landscape and offer targeted solutions for chronic disease management.
Leading companies are investing substantially in cell therapy by establishing state-of-the-art manufacturing facilities. The initiative reflects their confidence in cell therapies' potential and is a significant driver for the global cell therapy market. Significant investments in advanced production facilities enable increasing production capacity and scalability, resulting in a more efficient and widespread delivery of cell-based treatments. The proactive approach by major industry players fosters innovation and contributes to the overall growth and maturity of the global cell therapy market, solidifying their position as a transformative force in healthcare.
For instance, in October 2023, Bayer AG revealed its inaugural cell therapy launch facility in Berkeley, California, marking a pivotal step in their global initiative to provide cell therapies to patients. The USD 250 million, 100,000-square-foot facility is designed to meet the demand for materials in late-stage clinical trials and the potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy under assessment for Parkinson's disease treatment. The establishment of the cutting-edge facility underscores Bayer's commitment to advancing cell therapies on a global scale and signifies a significant investment in the future of innovative medical solutions.
Governments around the globe are collaborating with major companies to stimulate the growth of the global cell therapy market. These partnerships aim to leverage governmental support and expertise to advance research, development, and accessibility of cell therapies. By fostering such collaborations, policymakers seek to create a conducive environment for innovation, accelerate regulatory approvals, and ensure widespread adoption of these advanced medical interventions. The synergy between governments and key industry players reflects a shared commitment to realize the full potential of cell therapies in revolutionizing healthcare and addressing challenges on a global scale.
In September 2023, the United States government unveiled new measures as part of the Cancer Moonshot Initiative, a focal point in the battle against cancer. The initiative was led by President through the collaborative entity "CancerX," aiming to reduce the U.S. cancer death rate by 50% before 2047. The initiative includes prominent pharmaceutical companies and their partnership with digital healthcare solution providers such as Amazon and Intel. The Moffitt Cancer Center in Florida and the Digital Medicine Society (DiMe), a global non-profit of digital medicine experts, lead the effort.
The global cell therapy market is witnessing a growing demand for T-cell therapy. The innovative approach has gained prominence due to its remarkable success in treating certain cancers, especially hematologic malignancies. As clinical trials demonstrate its efficacy and safety, the demand for T-cell therapy is increasing. Patients, healthcare providers, and pharmaceutical companies recognize its potential to revolutionize cancer treatment by leveraging the body's immune system. The increasing demand is propelling research, development, and investment in T-cell therapies, contributing to the dynamic growth of global cell therapy market.
In March 2023, Thermo Fisher Scientific and Arsenal Biosciences, Inc., American companies, announced their strategic partnership to advance the manufacturing processes for novel cancer treatments. The collaboration emphasizes research and process development to establish a robust manufacturing framework for their cutting-edge, programmable autologous T cells designed for cancer treatment.
The global cell therapy market is poised for a promising future, driven by a convergence of factors highlighting its potential to revolutionize healthcare. Advancements in cell therapy technologies, including precision-enhancing techniques like CRISPR gene editing, are increasing the efficacy and scope of treatments. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, create a compelling need for innovative therapeutic solutions, positioning cell therapy at the forefront of medical breakthroughs. Collaborative partnerships between pharmaceutical companies, biotech firms, and academic institutions are accelerating research and development efforts, fostering a dynamic environment of innovation. Supportive regulatory frameworks and increasing stakeholder awareness contribute towards a favorable landscape for the market's growth. With expanding applications across diverse medical domains and a global commitment to addressing unmet healthcare needs, the cell therapy market is poised to play a pivotal role in shaping the future of healthcare.
Numerous major companies are actively forming collaborations in the global cell therapy market. These strategic partnerships facilitate the pooling of resources, expertise, and technologies to drive innovation and expedite the development of advanced cell-based therapies. By joining forces, these companies enhance their capabilities in research, clinical trials, and manufacturing processes, ultimately contributing to the evolution and expansion of the cell therapy market.
For instance, in August 2023, Astellas Pharma Inc. and Poseida Therapeutics, Inc. unveiled a strategic investment to bolster Poseida's pioneering efforts in redefining cancer cell therapy. In the financial arrangement, Astellas is set to invest a total of USD 50 million, comprising a USD 25 million acquisition of 8,333,333 shares of Poseida's common stock (representing around 8.8% of the total outstanding common stock) at USD 3.00 per share through a private placement. Additionally, a one-time payment of USD 25 million secures Astellas an exclusive negotiation and first refusal right to license Poseida's clinical stage program, P-MUC1C-ALLO1. The program involves the development of an allogeneic CAR-T cell therapy targeting multiple solid tumor indications.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.